WASHINGTON , Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2024: The Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024. A corporate presentation is scheduled for 9:45 a.m.
Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023 Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash ranges Fanapt® launch in bipolar I disorder; new patient starts increased by over 90% in Q3 2024 as compared to Q3 2023 Fanapt® long acting injectable program expected to be initiated in Q4 2024 Milsaperidone NDA for schizophreni...
Conference Call and Webcast to Follow WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2024 on Wednesday, November 6, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 6, 2024, during which management will discuss the third quarter 2024 fi...
Board Has Determined That Latest Proposal Is Not in the Best Interests of the Company or Stockholders WASHINGTON , Oct. 14, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it received a second unsolicited, non-binding proposal from Cycle Group Holdings Ltd. ("Cycle Group") to acquire the Company for $8.00 per share in cash.
UK-based Cycle Pharmaceuticals on Monday reaffirmed its offer to buy Vanda Pharmaceuticals in a deal that values the US drugmaker at $488 million, despite a regulatory setback for its stomach condition drug in September.
BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (“Cycle”), a dynamic leader in developing rare disease therapies, today reaffirmed its proposal to acquire all of the issued and outstanding shares of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) for an all-cash consideration of $8.00 per Vanda share. Cycle is making its renewed proposal public for the benefit of Va...
The biotech had discouraging news to report about one of its pipeline drugs. The FDA declined to approve its application.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.